Genetic Induction of the Warburg Effect Inhibits Tumor Growth

Mitochondrial carriers are integral proteins of the inner membrane that allow for the exchange of metabolites, nucleotides, and cofactors between the cytosol and the mitochondria and thus, enact a variety of energetic adjustments [1,2]. The mitochondrial citrate carrier, SLC25A1 or CIC, catalyses the efflux of citrate from the mitochondrial matrix in exchange for cytosolic malate. Mitochondrial citrate is necessary for the Krebs cycle and oxidative phosphorylation (OXOPHOS), while cytosolic citrate provides the only carbon source for fatty acids and sterol biosynthesis. In addition, cytoplasmic citrate is an allosteric inhibitor of enzymes involved in glucose catabolism, particularly of phosphofructokinase (PFK), while at the same time providing a source for the production of NAD+ (via the action of citrate lyase and malate dehydrogenase), which can be used to support glycolysis. Because tumor cells display enhanced glycolytic capacity and enhanced rates of de novo lipogenesis, these activities would theoretically place CIC at a nodal point in the regulation of metabolic pathways and mitochondrial activity in cancer. In this issue of Oncotarget, Avantaggiati and colleagues [3] provide novel findings that suggest that inhibition of tumor growth brought about by either genetic or biochemical inhibition of CIC occurs through unanticipated and fundamentally important new mechanisms that affect both cellular metabolism and viability. The authors show that while the inhibition of CIC blunted de novo lipid synthesis as expected, CIC inhibition also resulted in destabilization of the mitochondrial membrane potential, enhanced ROS (reactive oxygen species) production and increased production of L-lactate, indicative of a rewiring of metabolism towards glycolysis. The major implications of their findings is that a key component of CIC's ability to support proliferation of tumor cells might be in fact be the preservation of mitochondrial pathways of energy production while limiting the glycolytic addiction of tumor cells, essentially suppressing the Warburg effect, a metabolic trait that is proposed to promote malignancy. In addition, the authors provide compelling new evidence that CIC inhibition results in mitochondrial depletion and degradation via autophagy. In support of these data, blocking of autophagy rescues the anti-proliferative effects due to CIC loss both in tumor cells and in the model organism Zebrafish. These studies describe a previously unknown role for CIC in regulating mitochondrial homeostasis and autophagy/mitophagy and are important and provocative for several reasons. The Warburg theory proposes that the mitochondria of cancer cells are unable to provide energy via oxidative phosphorylation, and therefore rely upon glycolysis for …